Effects of suplatast tosilate on airway inflammation and interleukin-5 in asthmatic rats

• Published in: Zhongguo dang dai er ke za zhi Vol. 16; no. 7; p. 759
• Main Authors: Liu, Dan, Li, Yun, Zhong, Li-Li, Tan, Yu-Pin
• Format: Journal Article
• Language: Chinese
• Published: China 01.07.2014
• Subjects: Animals; Arylsulfonates - therapeutic use; Asthma - drug therapy; Asthma - immunology; Asthma - pathology; Eosinophils - drug effects; Interleukin-5 - analysis; Interleukin-5 - antagonists & inhibitors; Interleukin-5 - genetics; Lung - metabolism; Lung - pathology; Male; Rats; Rats, Sprague-Dawley; Sulfonium Compounds - therapeutic use
• ISSN: 1008-8830
• DOI: 10.7499/j.issn.1008-8830.2014.07.021

To study the effects of suplatast tosilate (IPD) on the airway inflammation and expression of interleukin-5 in asthmatic rats. Fifty adult male Sprague-Dawley rats (4-week- old) were randomly assigned to five groups: placebo control, untreated asthma, budesonide(BUD)-treated asthma , early or late IPD intervention group (n=10 rats each). Asthmatic mode was prepared by ovalbumin sensitizion and challenge. Inflammatory cells and the percentage of EOS were detected in bronchoalveolar lavage fluid (BALF). The lung tissues were removed to detect the lung histomorphology. Gene expression of IL-5 was measured by reverse transcription-polymerase chain reaction (RT-PCR). Levels of interleukin 5 (IL-5) in BALF were measured using ELISA. The inflammatory cells and the percentage of EOS in BALF, IL-5 levels in BALF and IL-5 mRNA expression in the lung tissues were obviously higher in the untreated asthma group than the control group (P<0.05), while the parameters in the IPD or BUD-treated asthma groups were significantly